44R0 Stock Overview
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Phio Pharmaceuticals Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.81 |
| 52 Week High | US$13.65 |
| 52 Week Low | US$3.14 |
| Beta | 1.53 |
| 1 Month Change | 0% |
| 3 Month Change | 0.73% |
| 1 Year Change | -57.42% |
| 3 Year Change | -71.34% |
| 5 Year Change | -99.59% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 44R0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | -57.4% | -19.4% | -0.4% |
Return vs Industry: 44R0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 44R0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 44R0 volatility | |
|---|---|
| 44R0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 44R0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 44R0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Bob Bitterman | www.phiopharma.com |
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy; PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in T and tumor cells; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. Fundamentals Summary
| 44R0 fundamental statistics | |
|---|---|
| Market cap | €5.27m |
| Earnings (TTM) | -€10.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 44R0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 44R0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$154.00k |
| Gross Profit | -US$154.00k |
| Other Expenses | US$11.33m |
| Earnings | -US$11.48m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 44R0 perform over the long term?
See historical performance and comparison